Фармакотерапия у взрослых с избыточной массой тела и ожирением: систематический обзор и сетевой мета-анализ рандомизированных контролируемых исследований
Перевод Г.Е. Заика (07.04.2024)
References
1. NCD Risk Factor Collaboration Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016; 387: 1377-1396 View in Article Scopus (3717) PubMed Summary Full TextFull Text PDFGoogle Scholar
2. Garvey WT Mechanick JI Brett EM et al.American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.Endocr Pract. 2016; 22: 1-2*3View in Article Scopus (938)PubMedSummaryFull TextFull Text PDFGoogle Scholar
3. Bray G A Frühbeck G Ryan DH Wilding JPH Management of obesity.Lancet. 2016; 387: 1947-1956 View in Article Scopus (658)PubMedSummaryFull TextFull Text PDFGoogle Scholar
4. Wharton S Lau DCW Vallis M et al. Obesity in adults: a clinical practice guideline.CMAJ. 2020; 192: e875-e891 View in Article Scopus (459)PubMedCrossrefGoogle Scholar
5. Lemstra M Bird Y Nwankwo C Rogers M Moraros J Weight loss intervention adherence and factors promoting adherence: a meta-analysis. Patient Prefer Adherence. 2016; 10: 1547-1559 View in Article Scopus (211) PubMed Crossref Google Scholar
6. Arterburn DE Telem DA Kushner RF Courcoulas AP Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020; 324: 879-887 View in Article Scopus (508) PubMed Crossref Google Scholar
7. Sarwer DB Ritter S Wadden TA Spitzer JC Vetter ML Moore RH Attitudes about the safety and efficacy of bariatric surgery among patients with type 2 diabetes and a body mass index of 30–40 kg/m2. Surg Obes Relat Dis. 2013; 9: 630-635 View in Article Scopus (34) PubMed Summary Full Text Full Text PDF Google Scholar
8. Bessesen DH Van Gaal LF Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol. 2018; 6: 237-248 View in Article Scopus (219) PubMed Summary Full Text Full Text PDF Google Scholar
9. Sharretts J Galescu O Gomatam S Andraca-Carrera E Hampp C Yanoff L Cancer risk associated with lorcaserin—the FDA's review of the CAMELLIA-TIMI 61 trial. N Engl J Med. 2020; 383: 1000-1002 View in Article Scopus (85)PubMedCrossrefGoogle Scholar
10. Wilding JPH Batterham RL Calanna S et al.Once-weekly semaglutide in adults with overweight or obesity.N Engl J Med. 2021; 384: 989-1002View in Article Scopus (1277) PubMed Crossref Google Scholar
11. Davies M Færch L Jeppesen OK et al.Se maglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021; 397: 971-984View in Article Scopus (421)PubMedSummaryFull TextFull Text PDFGoogle Scholar
12. Wadden TA Bailey TS Billings LK et al.Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial.JAMA. 2021; 325: 1403-1413 View in Article Scopus (374)PubMedCrossrefGoogle Scholar
13. Rubino D Abrahamsson N Davies M et al.Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial.JAMA. 2021; 325: 1414-1425View in Article Scopus (399) PubMed CrossrefGoogle Scholar
14. Hutton B Salanti G Caldwell DM et al.The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.Ann Intern Med. 2015; 162: 777-784View in Article Scopus (4332) PubMedCrossrefGoogle Scholar
15. Page MJ McKenzie JE Bossuyt PM et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71View in Article Scopus (27158) PubMedCrossrefGoogle Scholar
16. Rücker G Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012; 3: 312-324 View in Article PubMedCrossrefGoogle Scholar
17. Jackson D Bujkiewicz S Law M Riley RD White IR A matrix-based method of moments for fitting multivariate network meta-analysis models with multiple outcomes and random inconsistency effects.Biometrics. 2018; 74: 548-556View in Article Scopus (25) PubMed CrossrefGoogle Scholar
18. Rücker G Schwarzer G Resolve conflicting rankings of outcomes in network meta-analysis: partial ordering of treatments.Res Synth Methods. 2017; 8: 526-536 View in Article Scopus (44)PubMedCrossrefGoogle Scholar
19. Jackson D White IR Riley RD Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012; 31: 3805-3820 View in Article Scopus (453) PubMed Crossref Google Scholar
20. Krahn U Binder H König J A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013; 13: 35 View in Article Scopus (309) PubMed Crossref Google Scholar
21. Dias S Welton NJ Caldwell DM Ades AE Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010; 29: 932-944 View in Article Scopus (1577) PubMed Crossref Google Scholar
22. Schandelmaier S Briel M Varadhan R et al. Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses. CMAJ. 2020; 192: E901-E906 View in Article Scopus (236) PubMed Crossref Google Scholar
23. Sterne JAC Savović J Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366l4898 View in Article Google Scholar
24. Puhan MA Schünemann HJ Murad MH et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014; 349g5630 View in Article Scopus (1156) PubMed Crossref Google Scholar
25. Brignardello-Petersen R Bonner A Alexander PE et al. Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis. J Clin Epidemiol. 2018; 93: 36-44
26. Brignardello-Petersen R Florez ID Izcovich A et al. GRADE approach to dView in Article Scopus (410) PubMed Summary Full Text Full Text PDF Google Scholar rawing conclusions from a etwork meta-analysis using a minimally contextualised framework. BMJ. 2020; 371m3900 View in Article Google Scholar
27. Hultcrantz M Rind D Akl EA et al. The GRADE Working Group clarifies the construct of certainty of evidence. J Clin Epidemiol. 2017; 87: 4-13 View in Article Scopus (401)PubMedSummaryFull TextFull Text PDFGoogle Scholar
28. Zeng L Brignardello-Petersen R Hultcrantz M et al.GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainy of evidence ratings.J Clin Epidemiol. 2021; 137: 163-175 View in Article Scopus (94)PubMedSummaryFull TextFull Text PDFGoogle Scholar
29. Heymsfield SB Wadden TA Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017; 376: 254-266View in Article Scopus (977) PubMed Crossref Google Scholar
30. Center for Drug Evaluation and Research Guidance for industry developing products for weight management. US Food and Drug Administration, Rockville, MD2007 View in Article Google Scholar
31. Crosby RD Kolotkin RL Williams GR An integrated method to determine meaningful changes in health-related quality of life. J Clin Epidemiol. 2004; 57: 1153-1160 View in Article Scopus (125) PubMedSummaryFull TextFull Text PDFGoogle Scholar
32. Wing RR Lang W Wadden TA et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34: 1481-1486View in Article Scopus (1249)PubMed CrossrefGoogle Scholar
33. Hollander P Gupta AK Plodkowski R et al.Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013; 36: 4022-4029 View in Article Scopus (344)PubMedCrossrefGoogle Scholar
34. Guyatt G Montori V Devereaux PJ Schünemann H Bhandari M Patients at the centre: in our practice, and in our use of language. BMJ Evid Based Med. 2004; 9: 6-7 View in Article Scopus (16)CrossrefGoogle Scholar
35. Khera R Murad MH Chandar AK et al.Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis.JAMA. 2016; 315: 2424-2434View in Article Scopus (519)PubMedCrossref Google Scholar
36. Khera R Pandey A Chandar AK et al.Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis.Gastroenterology. 2018; 154: 1309-1319.e7 View in Article Scopus (53)PubMedSummaryFull Text Full Text PDFGoogle Scholar
37. Skrivanek Z Gaydos BL Chien JY et al. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014; 16: 748-756 View in Article PubMed CrossrefGoogle Scholar
38. Harreiter J Just I Leutner M et al. Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial. Diabetes Obes Metab. 2021; 23: 1129-1139View in Article PubMedGoogle Scholar
39. Thieu VT Robinson S Kennedy-Martin T Boye KS Garcia-Perez L-E Patient preferences for glucagon-like peptide 1 receptor-agonist treatment attributes. Patient Prefer Adherence. 2019; 13: 561-576 View in Article Scopus (28)PubMedCrossref Google Scholar
40. Horowitz M Aroda VR Han J Hardy E Rayner CK Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: incidence and consequences. Diabetes Obes Metab. 2017; 19: 672-681 View in Article Scopus (54) PubMed CrossrefGoogle Scholar
41. Gallagher C Corl A Dietz WH et al. Weight can't wait: a guide to discussing obesity and organizing treatment in the primary care setting. Obesity (Silver Spring). 2021; 29: 821-824View in Article Scopus (11)PubMedCrossrefGoogle Scholar
42. Bonnet F Scheen A Understanding and overcoming metformin gastrointestinal intolerance.Diabetes Obes Metab. 2017; 19: 473-481View in Article Scopus (144)PubMedCrossrefGoogle Scholar
43. Li S Vandvik PO Lytvyn L et al.SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.BMJ. 2021; 373n1091View in Article Google Scholar
Article info
Publication history
Published: 06 April 2024
Identification
DOI: https://doi.org/10.1016/S0140-6736(24)00351-9
Linked Articles
o Retraction and republication—Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials Full-Text PDF View full text